Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Controlling Infections Could Be Key to Improving Survival in CLL

September 9th 2021

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

Pirtobrutinib Shows Impressive Efficacy in Previously Treated CLL/SLL

September 9th 2021

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Coombs on the Efficacy Results of the BRUIN Study With Pirtobrutinib in CLL

September 9th 2021

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

Dr. Danilov on the Utility of BTK Inhibitors in CLL

September 8th 2021

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

CLL: Final Thoughts

September 7th 2021

An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.

Emerging Agents for R/R CLL

September 7th 2021

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Dr. Atallah on the Prognostic Role of Undetectable MRD in CLL

August 31st 2021

Ehab L. Atallah, MD, discusses the prognostic role of undetectable minimal residual disease in chronic lymphocytic leukemia.

PI3K inhibitors for R/R CLL

August 31st 2021

An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

CLL: Venetoclax in the R/R Setting

August 31st 2021

Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.

Emerging Strategies in the Management of Relapsed/Refractory CLL

August 30th 2021

Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.

Therapeutic Sequencing Strategies in Relapsed/Refractory CLL

August 30th 2021

Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.

Key Clinical Data in Relapsed/Refractory CLL

August 30th 2021

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

High-Risk Patients With R/R CLL

August 24th 2021

A discussion about treatment for high-risk patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

CLL: BTK Inhibitors in the R/R Setting

August 24th 2021

Nicole Lamanna, MD, provides an overview of Bruton's tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in the relapsed/refractory (R/R) setting.

Frontline Therapy for CLL: Emerging Agents and Approaches

August 23rd 2021

Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.

Which Path to Take in Frontline Therapy for CLL?

August 23rd 2021

Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.

Looking Toward the Future of CLL Management

August 23rd 2021

An expert hematologist/oncologist highlights key takeaways for the future management of chronic lymphocytic leukemia given an evolving therapeutic landscape.

Optimal Treatment Strategies for Chronic Lymphocytic Leukemia

August 23rd 2021

Practical advice on optimal toxicity management and sequencing of therapy in patients with chronic lymphocytic leukemia.

Acalabrutinib vs Ibrutinib: Head-to-Head Data in Previously Treated CLL

August 23rd 2021

Tara Graff, DO, MS, reflects on the head-to-head comparison data of acalabrutinib vs ibrutinib in patients with previously treated CLL.

Frontline BTKi Therapy in CLL: The ELEVATE-TN Study 4-Year Follow-up

August 23rd 2021

Expert insight on the use of frontline BTK inhibitor monotherapy over combination therapy in CLL regarding the ELEVATE-TN trial’s readout.